The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years

Asian Pacific Journal of Allergy and Immunology

Volumn 29, Issue 2, 2011, Pages 127-133

  Visitsunthorn, Nualanong ^a   Chirdjirapong, Varakorn ^a   Santadilog, Satit ^a   Pajarn, Panjama ^a   Jirapongsananuruk, Orathai ^a   Komoltri, Chulaluk ^b   Vichyanond, Pakit ^a  

^a Division of Allergy and Clinical Immunology   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Asthmatic children; Bronchial hyperreactivity; Cysteinyl leukotriene receptor antagonist; Montelukast

Indexed keywords

METHACHOLINE; MONTELUKAST; PLACEBO;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD CHEMISTRY; BRONCHUS HYPERREACTIVITY; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; TREATMENT DURATION; TREATMENT RESPONSE;

ACETATES; ADOLESCENT; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; QUINOLINES; RESPIRATORY FUNCTION TESTS; THAILAND; TREATMENT OUTCOME;

EID: 79959360949     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vichyanond P, Jirapongsananuruk O, Visitsuntorn N, Tuchinda M. Prevalence of asthma, rhinitis and eczema in children from the Bangkok area using the ISAAC (International study for Asthma and Allergy in Children) questionnaires. J Med Assoc Thai. 1998; 81: 175-84.
2. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996; 98: 1-13.
3. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998; 279: 1181-6.
4. Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest. 2007; 131: 180-6.
5. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med. 2000; 162: 187-90.
6. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999; 159: 1043-51.
7. Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 >75%. Curr Med Res Opin. 2004; 20: 1651-9.
8. Nelson KA, Smith SR, Trinkaus K, Jaffe DM. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care. 2008; 24: 21-7.
9. Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther. 2008; 30: 1026-35.
10. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet J, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999; 160: 1862-8.
11. Global Strategy for Asthma Management and Prevention. National Institutes of Heart, Lung and Blood Institute, 2002. NIH Publication No. 02-3659.
12. Kroegel C. Global Initiative for Asthma Management and Prevention--GINA 2006. Pneumologie. 2007; 61: 295-304.
13. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Firzgerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31: 143-78.
14. American Thoracic Society. Guidelines for methacholine and exercise challenge testing 1999 update. Am J Respir Crit Care Med. 2000; 161: 309-29.
15. Laird NM, Skinner J, Kenward M. An analysis of two-period crossover designs with carry-over effects. Stat Med. 1992; 11: 1967-79.
16. Tudor G, Koch GG. Review of nonparametric methods for the analysis of crossover studies. Stat Methods Med Res. 1994; 3: 345-81.
17. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006; 173: 379-85.
18. Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. The interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma, and asthma symptoms. Am Rev Respir Dis. 1990; 142: 549-54.
19. Amirav I. Real-life effectiveness of Singulair (montelukast) in 506 children with mild to moderate asthma. Isr Med Assoc J. 2008; 10: 287-91.
20. Karaman O, Sünneli L, Uzuner N, Islekel H, Turgut CS, Köse S, et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids Allergol Immunopathol (Madr). 2004; 32: 21-7.
21. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 1999; 14: 12-8.
22. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest. 2002; 121: 732-8.
23. Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007; 28: 296-304.
24. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007; 67: 887-901.
25. Ehlayel MS, Bener A, Sabbah A. Montelukast treatment in children with moderately severe atopic dermatitis. Eur Ann Allergy Clin Immunol. 2007; 39: 232-6.
26. Bisgaard H, Loland L, Oj JA. NO in Exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med. 1999; 160: 1227-31.